STOCK TITAN

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Leap Therapeutics (Nasdaq: LPTX), a biotech company specializing in targeted and immuno-oncology therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. Douglas E. Onsi, President and CEO, will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 4:00 p.m. Eastern Time. The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for time viewing.

Leap Therapeutics (Nasdaq: LPTX), un'azienda biotech specializzata in terapie oncologiche mirate e immunologiche, ha annunciato la sua partecipazione alla 36ª Conferenza Sanitaria Annuale di Piper Sandler a New York. Douglas E. Onsi, Presidente e CEO, parteciperà a una chiacchierata informale programmata per mercoledì 4 dicembre 2024, alle 16:00 ora orientale. La presentazione sarà accessibile tramite webcast dal vivo sul sito web delle relazioni con gli investitori della società, con una registrazione disponibile per la visione successiva.

Leap Therapeutics (Nasdaq: LPTX), una empresa biotecnológica especializada en terapias oncológicas dirigidas e de inmuno-oncología, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York. Douglas E. Onsi, Presidente y CEO, participará en una charla informal programada para el miércoles 4 de diciembre de 2024, a las 4:00 p.m. hora del Este. La presentación estará disponible a través de una transmisión en vivo en el sitio web de relaciones con inversores de la compañía, con una repetición disponible para su visualización posterior.

Leap Therapeutics (Nasdaq: LPTX), 표적 및 면역 종양학 치료제를 전문으로 하는 생명공학 회사가 뉴욕에서 열리는 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Douglas E. Onsi 사장 겸 CEO가 2024년 12월 4일 수요일 오후 4시(동부 표준시)에 예정된 파이어사이드 채팅에 참여할 예정입니다. 프레젠테이션은 회사 투자자 관계 웹사이트를 통해 라이브 웹캐스트로 시청할 수 있으며, 이후 다시 보기가 가능합니다.

Leap Therapeutics (Nasdaq: LPTX), une entreprise biopharmaceutique spécialisée dans les thérapies ciblées et d'immuno-oncologie, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler à New York. Douglas E. Onsi, Président et PDG, participera à une discussion informelle prévue le mercredi 4 décembre 2024, à 16h00, heure de l'Est. La présentation sera accessible via un webinaire en direct sur le site des relations avec les investisseurs de l’entreprise, avec une rediffusion disponible pour une visualisation ultérieure.

Leap Therapeutics (Nasdaq: LPTX), ein Biotech-Unternehmen, das sich auf zielgerichtete und immunonkologische Therapien spezialisiert hat, hat seine Teilnahme an der 36. Jahreskonferenz für Gesundheit von Piper Sandler in New York bekannt gegeben. Douglas E. Onsi, Präsident und CEO, wird an einem geplanten Fireside-Chat am Mittwoch, den 4. Dezember 2024, um 16:00 Uhr Eastern Time teilnehmen. Die Präsentation wird über ein Live-Webcast auf der Website der Investor Relations des Unternehmens zugänglich sein, mit einer späteren Wiederholung zur Einsichtnahme.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York, NY.

Leap Presentation Details:

Piper Sandler 36th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Time: 4:00 p.m. Eastern Time

A live webcast of the fireside chat may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time.

About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com

Leap Therapeutics logo (PRNewsfoto/LEAP Therapeutics)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-piper-sandler-36th-annual-healthcare-conference-302313181.html

SOURCE Leap Therapeutics, Inc.

FAQ

When is Leap Therapeutics (LPTX) presenting at the Piper Sandler Healthcare Conference 2024?

Leap Therapeutics (LPTX) is presenting on Wednesday, December 4, 2024, at 4:00 p.m. Eastern Time.

How can I watch Leap Therapeutics' (LPTX) presentation at the Piper Sandler Conference?

The presentation can be watched via live webcast on Leap Therapeutics' investor relations website at https://investors.leaptx.com/, where a replay will also be available.

What type of presentation will Leap Therapeutics (LPTX) give at the Piper Sandler Conference?

Leap Therapeutics will participate in a fireside chat format presentation at the conference.

Where is the Piper Sandler Healthcare Conference 2024 being held?

The Piper Sandler 36th Annual Healthcare Conference is being held in New York, NY.

Leap Therapeutic

NASDAQ:LPTX

LPTX Rankings

LPTX Latest News

LPTX Stock Data

18.50M
37.01M
17.29%
40.3%
2.64%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE